StreetAlpha.app
Home › Stocks › EQ

Equillium, Inc. (EQ)

Healthcare
$1.21
▲ +5.22%
LAST CLOSE · NOV 17

Equillium is a La Jolla biotechnology company developing treatments for autoimmune and inflammatory diseases, starting with ulcerative colitis. It last closed at $1.21 on Nov 17, up 5.22% on the day.

AI Auto Pilots
Is EQ in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$18.4M
EPS (diluted)
−$0.12
Free cash flow
−$15.5M
Valuation
Market cap
$99.6M
82.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.3M
At Sep 30
Shareholder equity
$52.7M
Shares outstanding
82.3M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$39.1M−$39.1MFY2021FY2022: −$62.4M−$62.4MFY2022FY2023: −$13.3M−$13.3MFY2023FY2024: −$8.1M−$8.1MFY2024FY2025: −$22.4M−$22.4MFY2025

From EQ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated EQ in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 891.7% upside

Based on 1 analyst who set a price target on EQ in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.21.

Low $12.00Avg $12.00High $12.00
Blue marker: last close $1.21
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
Roth CapitalReiterated
Sep 4Buy$12
Piper SandlerInitiated
Jul 13Buy$20
Leerink PartnersUpgrade
May 28Buy$6
B. Riley SecuritiesInitiated
Apr 16Buy$6
Raymond JamesInitiated
Apr 14Buy$6
DateFirmActionRatingPrice target
Sep 4Roth CapitalReiteratedBuy$12
Jul 13Piper SandlerInitiatedBuy$20
May 28Leerink PartnersUpgradeBuy$6
Apr 16B. Riley SecuritiesInitiatedBuy$6
Apr 14Raymond JamesInitiatedBuy$6
Loading…

Technical Analysis

EQ · as of the Nov 17 close · updated after every close
Downtrend

The stock is 12% below its 20 day and 28% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $1.20, and the nearest resistance the Pivot R1 at $1.25.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 10.1%/day
Key levels
$3.5452 week high+192.6%
$2.09200 day average+72.7%
$2.01100 day average+66.1%
$1.5550 day average+28.1%
$1.48Swing high (Oct 29)+22.3%
$1.3620 day average+12.4%
$1.25Pivot R1+3.3%
$1.21Last close
$1.20Pivot−0.8%
$1.17Swing low (Oct 26)−3.3%
$1.16Pivot S1−4.1%
$0.8152 week low−33.1%
Indicators
RSI (14)38.70Weak, oversold below 30Neutral
MACD-0.07Below its signal lineBearish
Stochastic10.9Near the bottom of its rangeOversold
ADX (14)18.3No clear trend
Williams %R-85.1Oversold below −80, overbought above −20Oversold
CCI (20)-136.3Oversold below −100, overbought above 100Oversold
Rate of change−14.2%Change over 10 sessionsBearish
ATR (14)$0.12Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EQ

What happened before

See how EQ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EQ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EQ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EQ in the last 90 days.

Loading…

See today’s whale options flow across the market →

EQ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 27 selling
  • ▼Held by funds -1.0 pts
  • ▲Funds holding +5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6560+8.3%
In funds' top 10110.0%
Held by funds49.7%50.7%−1.0 pts
New / increased15 / 1718 / 17−8.6%
Reduced / sold out18 / 914 / 8+22.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EQ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EQ is in one of them and how their past EQ trades turned out.

EQ in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EQ in an article yet. Here's the latest on the wider market.

About Equillium

Equillium is a biotechnology company in La Jolla, California, that develops treatments for severe autoimmune and inflammatory diseases. Its lead candidate, EQ504, works on the aryl hydrocarbon receptor and is being developed first for ulcerative colitis and other gut diseases. The company also has an oral candidate, EQ302, that blocks two inflammatory signaling proteins and is aimed at celiac disease. Both candidates are still in development and not yet sold, with patients who have gut and immune disorders as the intended users.

Headquarters
La Jolla, CA